Phaseline

Targets › NAC

NAC (NACHT, LRR and PYD domains-containing protein 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology.

Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis. Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation. (UniProt, Q9C000)

Open in Phaseline: the race on NAC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ScandiBio TherapeuticsCMA2
Combined metabolic activator containing N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicot
NAC, LCAT, NICOTINAMIDE, L-SERINEPhase 3Alzheimer Disease–

Conditions

Alzheimer Disease (1)

Modalities

small molecule (1)

Companies

ScandiBio Therapeutics (1)

Related targets

LCAT (1) NICOTINAMIDE (1) L-SERINE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.